DRMA · Insider Trading
Dermata Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by DRMA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Kyri K. Van Hoose | SVP, CFO | A | +102,040 | — |
| 2026-08-18 | Gerald T Proehl | PRESIDENT, CHAIRMAN, CEO | A | +170,068 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kyri K. Van Hoose | SVP, CFO | 232,463 | $179.00K |
| Gerald T Proehl | PRESIDENT, CHAIRMAN, CEO | 31 | $24 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DRMA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.